Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003034910 | SCV003331317 | uncertain significance | Ataxia-telangiectasia syndrome | 2022-10-03 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with ATM-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces serine, which is neutral and polar, with tyrosine, which is neutral and polar, at codon 1037 of the ATM protein (p.Ser1037Tyr). |
Ambry Genetics | RCV004068682 | SCV005037683 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-01-27 | criteria provided, single submitter | clinical testing | The p.S1037Y variant (also known as c.3110C>A), located in coding exon 20 of the ATM gene, results from a C to A substitution at nucleotide position 3110. The serine at codon 1037 is replaced by tyrosine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |